From a therapeutic perspective, GLP-1R agonists are already approved for the treatment of type 2 diabetes and obesity, with well-established safety and pharmacokinetic profiles in humans [88]. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.